MANTLE CELL LYMPHOMA (MCL)
Clinical trials for MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for aggressive blood cancer
Disease control OngoingThis early-stage study is testing whether adding a new drug called acalabrutinib to standard lymphoma treatments is safe and effective for people with mantle cell lymphoma. The trial involves 72 adults who either haven't received treatment before or whose cancer has returned. Res…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Apr 01, 2026 21:40 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancer
Disease control OngoingThis study tested an oral medication called ACP-196 (acalabrutinib) for people with mantle cell lymphoma that has returned or stopped responding to previous treatments. Participants took the medication twice daily for as long as it worked and was tolerated. The main goal was to m…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for Tough-to-Treat lymphoma patients
Disease control OngoingThis study is testing an oral medication called rocbrutinib for people with mantle cell lymphoma whose cancer has returned or stopped responding to previous treatments, including other similar drugs. About 62 participants will take the medication to see how well it shrinks tumors…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Trial tests if powerful new drug trio can control lymphoma, then let patients stop treatment
Disease control OngoingThis study is testing a combination of three targeted drugs (acalabrutinib, venetoclax, and rituximab) for adults newly diagnosed with mantle cell lymphoma, a type of blood cancer. The main goal is to see if this chemotherapy-free approach can put the cancer into a very deep remi…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC